Mobidiag Extends Agreement With Biomedica Medizinprodukte Gmbh & Co KG For Distribution Of Amplidiag Diagnostics Tests In Central And Eastern Europe (CEE)

ESPOO, Finland--(BUSINESS WIRE)--Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with Biomedica Medizinprodukte GmbH & Co KG, provider of a large panel of medical products for health professionals, medical scientists, and research laboratories, for the distribution of the Amplidiag® product line. Under this new agreement Biomedica Medizinprodukte becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Central and Eastern Europe (Austria, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia).

“Rapid and reliable detection of gastrointestinal infections is crucial for preventing transmission of contagious pathogens. With Amplidiag products, we will ensure the distribution of innovative, quality products that will significantly impact infection control”

“Since Mobidiag’s inception, we have been focusing our activity towards Nordic region and France mainly. Three months ago, we have started developing our distribution network by extending our European coverage to Spain and Benelux. We are very pleased today to expand Amplidiag accessibility to Central and Eastern Europe with the support of our partner, Biomedica Medizinprodukte” said Tuomas Tenkanen, CEO at Mobidiag.

“Rapid and reliable detection of gastrointestinal infections is crucial for preventing transmission of contagious pathogens. With Amplidiag products, we will ensure the distribution of innovative, quality products that will significantly impact infection control” said Dr. Michaela Weblacher, Executive Vice President at Biomedica.

The distribution agreement is effective immediately and covers all Amplidiag® products (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE, Amplidiag® Easy and upcoming Amplidiag® Viral GE).

About Amplidiag®
Amplidiag® are innovative multiplex tests for the detection of gastrointestinal infections. They allow to screen simultaneously panels of the most relevant gastrointestinal pathogens. Based on well-established real-time PCR technology, they ensure optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings.

About Mobidiag
Established in 2000, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with a subsidiary in Paris, France.

In addition to Amplidiag® assays, Mobidiag is able to address both high volume and on demand testing with the new Amplidiag® Easy platform, bringing the Amplidiag® suite further by automating the workflow from sample to results, and the upcoming Novodiag® platform & associated panels for a fully automated solution and suitable for smaller volumes and labs.
Visit www.mobidiag.com for more information.

About Biomedica Medizinprodukte GmbH & Co KG
With 13 offices in Central and Eastern Europe (CEE) and a team of more than 250 professionals, Biomedica is a leading distributor of medical devices, in-vitro diagnostics, products for life sciences, Biomedica Immunoassays and Clinical IT. With its headquarter in Vienna, Austria, Biomedica is dedicated to strive for excellence, i.e. state-of-the-art products, uncompromising professionalism in customer support and the best possible service, in order to meet all customer demands at the highest level.